Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$9.85B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  AMLX

Amylyx Pharmaceuticals, Inc.

AMLX
62 / 100
$19.00arrow_drop_up8.20%$1.44

Income Statement (AMLX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
EBIT$1.93M$18.72M$20.20M-$2.25M-$44.77M
EBITDA$2.23M$19.02M$20.48M-$2.05M-$44.59M
gross Profit$99.08M$97.47M$92.63M$66.14M$19.06M
NET Income$4.73M$20.89M$22.07M$1.57M-$42.70M
total Revenue$108.44M$102.69M$98.21M$71.42M$21.88M

Balance Sheet (AMLX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
cash Equivalents-----
net Debt-$165.96M-$130.49M-$242.47M-$108.77M-$56.24M
stockholders Equity$433.43M$418.40M$386.36M$352.64M$340.60M
total Assets$517.45M$466.58M$453.58M$407.95M$391.45M
total Debt$4.23M$4.76M$5.28M$5.78M$6.27M
total Liabilities$84.02M$48.18M$67.22M$55.31M$50.84M

Cash Flow (AMLX)

itemDec 2023Sep 2023Jun 2023Mar 2023Dec 2022
financing Cash Flow$230.00K$889.00K$1.38M$1.04M$232.16M
free Cash Flow$13.19M-$5.52M$8.33M-$5.32M-$50.31M
investing Cash Flow--$123.22M$55.99M-$228.18M
operating Cash Flow$13.55M-$5.16M$8.60M-$5.07M-$49.69M

Amylyx Pharmaceuticals, Inc. (AMLX) Financials

Amylyx Pharmaceuticals, Inc. (AMLX) is a company specializing in the development and commercialization of innovative therapeutic solutions for neurodegenerative diseases. As part of their financials, the company provides detailed information about their income statement. The income statement outlines the company's revenues, expenses, and profits over a specific period. It includes important metrics such as gross profit and net income from stockholders. This statement helps investors and stakeholders understand the financial performance of Amylyx Pharmaceuticals.

Another crucial metric to consider is EBIT, which stands for earnings before interest and taxes. EBIT represents the company's operational profitability before deducting interest expenses and taxes. It provides insight into how well Amylyx Pharmaceuticals' core business is generating profits. Additionally, EBITDA (earnings before interest, taxes, depreciation, and amortization) is an important financial measure. It reflects the company's operating profitability, excluding depreciation and amortization expenses. EBITDA can be useful in assessing Amylyx Pharmaceuticals' ability to generate cash flow from its operations.

Turning to the balance sheet, it provides a snapshot of the company's financial position at a specific point in time. It lists the company's assets, liabilities, and stockholders' equity. Total assets represent the value of all resources owned by Amylyx Pharmaceuticals, including cash equivalents, investments, and property. On the other hand, total liabilities encompass the company's debts and obligations. Stockholders' equity indicates the residual interest in the company's assets after deducting liabilities. It signifies the shareholders' ownership in Amylyx Pharmaceuticals.

In terms of cash flow, Amylyx Pharmaceuticals' cash flow statement is essential for understanding the company's cash inflows and outflows. It consists of three main activities: operating, investing, and financing. Operating cash flow reflects the cash generated from the company's core operations, such as selling products or providing services. Investing cash flow showcases the cash used for acquiring or selling assets, as well as investments in research and development. Financing cash flow represents the money obtained or paid back to investors and lenders, including the issuance of stocks or repayment of loans. These cash flow activities provide insights into how Amylyx Pharmaceuticals manages its cash resources.

Lastly, free cash flow is a critical measure for Amylyx Pharmaceuticals' financial health. It represents the cash generated by the company's operations after accounting for capital expenditures. Free cash flow can be used for various purposes, such as reinvesting in the business, paying dividends, or reducing debt. It is an important indicator of the company's ability to generate cash and its potential for future growth.

In conclusion, understanding Amylyx Pharmaceuticals' financials is crucial for investors and stakeholders. Key financial statements like the income statement, balance sheet, and cash flow statement provide valuable insights into the company's performance, profitability, and financial position. By analyzing these metrics, stakeholders can make informed decisions and assess the potential of Amylyx Pharmaceuticals as an investment opportunity.

add Amylyx Pharmaceuticals, Inc. to watchlist

Keep an eye on Amylyx Pharmaceuticals, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.